Evidence map›Paper›PMID 30353942›Full record

ArticleEuropean journal of neurology2019

Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel.

K Ray Chaudhuri, A Antonini, W Z Robieson, O Sanchez-Soliño, L Bergmann, W Poewe, GLORIA study co-investigators

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review.Movement disorders : official journal of the Movement Disorder Society · 2021
    Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Observational
  10. Article
  11. Review
  12. Review
  13. Observational
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

K Ray ChaudhuriParkinson Foundation International Centre of Excellence, King's College Hospital, Denmark Hill, London, UK.ORCID 0000-0003-2815-0505
A AntoniniDepartment of Neuroscience, University of Padua, Padua, Italy.ORCID 0000-0003-1040-2807
W Z RobiesonAbbVie Inc., North Chicago, IL, USA.
O Sanchez-SoliñoAbbVie Inc., North Chicago, IL, USA.
L BergmannAbbVie Inc., North Chicago, IL, USA.
W PoeweMedical University of Innsbruck, Innsbruck, Austria.
GLORIA study co-investigators

Funding

AbbVie, Inc.
6 · The paper itself

Abstract

background and purposeGLORIA, a registry conducted with 375 advanced Parkinson's disease patients treated with levodopa-carbidopa intestinal gel (LCIG) for 24 months in routine clinical care, demonstrated significant reductions from baseline in 'off' time and 'on' time with dyskinesia and improvements in the Non-Motor Symptom Scale (NMSS) total and individual domain scores, and in Parkinson's Disease Questionnaire 8 item (PDQ-8) total score.

methodsAssociations between baseline NMSS burden (NMSB), the multi-domain NMSS total score and the PDQ-8 total score were investigated for 233 patients. Baseline NMSB was assigned to five numerical categories defined by the NMSS total cutoff scores (0-20, 21-40, 41-60, 61-80 and >80). Pearson and Spearman correlations were calculated at month 24.

resultsThe response of LCIG was assessed using validated criteria after 24 months. The proportion of patients decreasing ≥ 30 NMSS score points was 47% in the most affected NMSB category (NMSS total score > 80). A positive association was noted between baseline NMSB and NMSS total score (0.57, P < 0.0001), as well as between NMSS total score and PDQ-8 total score (0.46, P < 0.0001). Associations between improvements of the NMSS domain sleep/fatigue and PDQ-8 total score (0.32, P = 0.0001) as well as between the NMSS domain mood/cognition and PDQ-8 total score (0.37, P < 0.0001) were also shown.

conclusionsThis analysis demonstrated positive associations between NMSS baseline burden and improvements of non-motor symptoms. Improvements of non-motor symptoms were associated with improved quality of life in advanced parkinsonian patients during a 2-year treatment with LCIG and reflect the long-term non-motor efficacy of this treatment.

Indexed as

Quality of LifeAgedAntiparkinson AgentsCarbidopaCost of IllnessDrug CombinationsFemaleGelsHumansLevodopaMaleMiddle AgedParkinson DiseaseSeverity of Illness IndexSurveys and QuestionnairesTreatment OutcomeAntiparkinson AgentsCarbidopacarbidopa, levodopa drug combinationDrug CombinationsGelsLevodopalevodopa-carbidopa intestinal gelnon-motor symptomsParkinson's diseasequality of liferoutine patient care

Identifiers

PMID30353942
PMCPMC6590168

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.